Short answer: The retatrutide phase 2 trial (338 adults, NEJM 2023) reported mean weight loss of up to 24.2 percent at 48 weeks but did not publish regional body composition data, so the gluteal flattening that online communities call "RETA ass" cannot be read from the retatrutide dataset itself. Across GLP-1 receptor agonist trials, DEXA studies put lean mass at 25 to 40 percent of total weight lost, and exercise and protein intake studies show that ratio can be shifted. The pattern belongs to rapid, large weight loss as a class effect, not to one molecule.
Rapid, significant weight loss from GLP-1 receptor agonist research has drawn attention to a pattern that online communities have named "RETA ass": visible gluteal flattening associated with loss of both subcutaneous fat and lean tissue in the hip region. The term is colloquial, but the underlying body composition question is real and measurable.
The phase 2 trial of retatrutide (Jastreboff et al., New England Journal of Medicine, 2023) enrolled 338 adults with obesity and reported mean body weight reductions of up to 24.2% at 48 weeks in the highest-exposure groups. These numbers are significant, exceeding the weight reductions observed in earlier GLP-1 receptor agonist trials of tirzepatide and semaglutide.
The trial focused on total body weight, BMI, and metabolic parameters. It did not publish granular, region-specific DEXA body composition data for the gluteal area. The body composition question, including fat-free mass changes, has been addressed in related GLP-1 agonist literature rather than in the retatrutide dataset specifically.
Weight loss from any mechanism involves some proportion of lean tissue loss alongside fat reduction. In pharmacological weight loss research, the ratio of lean mass loss to total weight loss has consistently fallen between 25% and 40% in published DEXA studies across multiple GLP-1 receptor agonist trials.
A 2023 analysis of semaglutide 2.4 mg (the STEP trials, Wilding et al.) found that approximately 39% of total weight lost was lean mass. Tirzepatide data from SURMOUNT-1 reported a somewhat lower lean mass fraction, but the overall pattern holds: significant pharmacological weight reduction affects both fat and lean tissue.
Gluteal changes are particularly noticeable because the gluteal region carries both subcutaneous fat and significant muscle mass. Losing both simultaneously produces a visible contour change that is disproportionately apparent relative to total percentage of body weight lost.
A growing body of evidence examines whether structured resistance training preserves lean mass during pharmacological weight loss. Key findings from the published literature:
A 2024 study (Lundgren et al., published in The Lancet Diabetes & Endocrinology) randomized liraglutide-assigned participants to supervised resistance training versus usual activity. The exercise group retained significantly more lean mass and showed improved functional capacity compared to controls, while total weight reduction was similar between groups.
These findings are consistent with the general exercise physiology literature: mechanical loading signals muscle protein synthesis pathways even when the body is in caloric deficit. The gluteal muscles (gluteus maximus, medius, and minimus) are among the largest muscle groups in the body and respond measurably to targeted resistance loading.
Adequate protein intake during weight loss is one of the most replicated findings in body composition research. Meta-analyses (Hector & Phillips, 2018; Wycherley et al., 2012) consistently show that higher protein intake during caloric deficit preserves more lean body mass compared to standard or low protein intakes.
In the context of GLP-1 receptor agonist-induced appetite suppression, total caloric intake often drops substantially. If protein intake drops proportionally, the lean mass preservation signal weakens. Several research groups have noted that tracking macronutrient composition during pharmacological weight loss is an underexplored variable that may explain variation in body composition outcomes between individuals and across studies.
The studies referenced above were conducted in regulated clinical settings with defined populations, standardized protocols, and ethics oversight. Their findings describe group-level observations.
Vitality Peps compounds are intended for laboratory research purposes only. They are not for human consumption. Nothing in this article constitutes personal advice, and no reader should interpret published trial data as a protocol for individual application.
Researchers interested in body composition endpoints during multi-receptor agonist studies should consult the primary literature referenced below and design their investigations under appropriate institutional oversight.
No. The phase 2 trial reported total body weight, BMI and metabolic parameters. Regional DEXA data for the gluteal area was not published, so the body composition question is answered from related GLP-1 receptor agonist literature, not from the retatrutide dataset.
Published DEXA analyses across the class report lean mass at roughly 25 to 40 percent of total weight lost; the STEP 1 semaglutide analysis reported about 39 percent, and SURMOUNT-1 tirzepatide data a somewhat lower fraction. The exact share varies by trial, method and participant.
No. In research terms it is a regional lean mass deficit compounded by subcutaneous fat loss, and it appears wherever weight loss is substantial and rapid across the GLP-1 receptor agonist class. Retatrutide draws attention because its trial weight loss figures are the largest published so far.
Trials that add regional DEXA or BIA measurements, record physical activity and protein intake, and include structured exercise arms, such as the liraglutide plus exercise work published in 2024. Those variables are confounders that future retatrutide studies would need to control or record.
No. The trial evaluated a defined investigational product under clinical oversight. Research-grade retatrutide is a laboratory reagent supplied for research use only, with no clinical evidence of its own and no marketing authorisation anywhere.